Top

Published in:

Open Access 01-12-2018 | Research

Profiling of intracellular metabolites produced from galactose and its potential for galactosemia research

Authors: Michel van Weeghel, Lindsey Welling, Eileen P. Treacy, Ronald J. A. Wanders, Sacha Ferdinandusse, Annet M. Bosch

Published in: Orphanet Journal of Rare Diseases | Issue 1/2018

Abstract

Background

Clinical outcome of patients with a classical presentation of galactosemia (classical patients) varies substantially, even between patients with the same genotype. With current biomarkers, it is not possible to predict clinical outcome early in life. The aim of this study was to develop a method to provide more insight into galactose metabolism, which allows quantitative assessment of residual galactose metabolism in galactosemia patients. We therefore developed a method for galactose metabolite profiling (GMP) in fibroblasts using [U-¹³C]-labeled galactose.

Methods

GMP analysis was performed in fibroblasts of three classical patients, three variant patients and three healthy controls. The following metabolites were analyzed: [U¹³C]-galactose, [U¹³C]-galactose-1-phosphate (Gal-1-P) and [¹³C₆]- uridine diphosphate(UDP)-galactose. The ratio of [U¹³C]-Gal-1-P/ [¹³C₆]-UDP-galactose was defined as the galactose index (GI).

Results

All patient cell lines could be distinguished from the control cell lines and there was a clear difference between variant and classical patients. Variant patients had lower levels of [U¹³C]-galactose and [U¹³C]-Gal-1-P than classical patients (though substantially higher than healthy controls) and higher levels of [¹³C₆]-UDP-galactose than classical patients (though substantially lower than healthy controls) resulting in a different GI in all groups.

Conclusions

GMP in fibroblasts is a sensitive method to determine residual galactose metabolism capacity, which can discriminate between patients with a classical presentation of galactosemia, patients with a variant presentation and healthy controls. GMP may be a useful method for early prognostication after further validation in a larger cohort of patients representing the full phenotypic spectrum of galactosemia.

Kaufman FR, Kogut MD, Donnell GN, Goebelsmann U, March C, Koch R. Hypergonadotropic hypogonadism in female patients with galactosemia. N Engl J Med. 1981;304(17):994–8.CrossRefPubMed

Donnell GN, Collado M, Koch R. Growth and development of children with galactosemia. J Pediatr. (Donnell, Collado, Koch) Metab. Res. Labs and child. Developm. Clin., child. Hosp., los Angeles, calif G.N. Donnell, Metab. Res. Labs and child. Developm. Clin., child. Hosp., los Angeles. Calif. 1961;58(6):845–51.

Komrower GM, Lee DH. Long-term follow-up of galactosaemia. Arch Dis Child. 1970;45(241):367–73.CrossRefPubMedPubMedCentral

Waisbren SE, Norman TR, Schnell RR, Levy HL. Speech and language deficits in early-treated children with galactosemia. J Pediatr. 1983;102(1):75–7.CrossRefPubMed

Kaufman FR, Reichardt JK, Ng WG, Xu YK, Manis FR, McBride-Chang C, et al. Correlation of cognitive, neurologic, and ovarian outcome with the Q188R mutation of the galactose-1-phosphate uridyltransferase gene. J Pediatr. 1994 Aug;125(2):225–7.CrossRefPubMed

Huidekoper HH, Bosch AM, Van Der Crabben SN, Sauerwein HP, Ackermans MT, Wijburg FA. Short-term exogenous galactose supplementation does not influence rate of appearance of galactose in patients with classical galactosemia. Mol Genet Metab. 2005;84(3 SPEC. ISS.):265–72.

Berry GT, Nissim I, Lin Z, Mazur AT, Gibson JB, Segal S. Endogenous synthesis of galactose in normal men and patients with hereditary galactosaemia. Lancet. 1995 Oct 21;346(8982):1073–4.CrossRefPubMed

Prydz K, Dalen KT. Synthesis and sorting of proteoglycans. J Cell Sci. 2000 Jan;113(Pt 2):193–205.PubMed

Hayashi T, Maclachlan G. Glycolipids and glycoproteins formed from UDP-galactose by pea membranes. Phytochemistry Pergamon. 1984 Jan 1;23(3):487–92.CrossRef

10.

Coman DJ, Murray DW, Byrne JC, Rudd PM, Bagaglia PM, Doran PD, et al. Galactosemia, a single gene disorder with epigenetic consequences. Pediatr Res. National Centre for Inherited Metabolic Disorders, Children’s University Hospital, Dublin 1, Ireland.; 2010;67:286–92.

11.

Hughes J, Ryan S, Lambert D, Geoghegan O, Clark A, Rogers Y, et al. Outcomes of siblings with classical galactosemia. J Pediatr. National Centre for Inherited Metabolic Disorders, Children’s University Hospital, Dublin, Ireland; 2009 May;154(1097–6833 (Electronic)):721–6.

12.

Coss KP, Doran PP, Owoeye C, Codd MB, Hamid N, Mayne PD, et al. Classical Galactosaemia in Ireland: incidence, complications and outcomes of treatment. J Inherit Metab Dis. 2013 Jan;36(1):21–7.CrossRefPubMed

13.

Bosch AM. Classical galactosaemia revisited. J Inherit Metab Dis. (Bosch) Department of Pediatrics, Academic Medical Centre, University Hospital of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, Netherlands; 2006;29:516–25.

14.

Fridovich-Keil JL, Walter JH. Galactosaemia chapter 72. D. Valle, B. Vogelstein, K.W. Kinzler, S.E. Antonarakis, A. Ballabio (Eds.), et al., The Online Metabolic and Molecular Bases of Inherited Disease, OMMBID, Part 7: Carbohydrates, McGraw Hill, New York (2008)(Chapter 72). 2008;

15.

Knerr I, Coss KP, Kratzsch J, Crushell E, Clark A, Doran P, et al. Effects of temporary low-dose galactose supplements in children aged 5-12 y with classical galactosemia: a pilot study. Pediatr Res. 2015;78(3):272–9.CrossRefPubMed

16.

Welling L, Boelen A, Derks TGJ, Schielen PCJI, de Vries M, Williams M, et al. Nine years of newborn screening for classical galactosemia in the Netherlands: effectiveness of screening methods, and identification of patients with previously unreported phenotypes. Mol Genet Metab. 2017;120(3):223–8.CrossRefPubMed

17.

Coss KP, Treacy EP, Cotter EJ, Knerr I, Murray DW, Shin YS, et al. Systemic gene dysregulation in classical Galactosaemia: is there a central mechanism? Mol Genet Metab. 2014;113(3):177–87.CrossRefPubMed

18.

Diekman EF, Ferdinandusse S, van der Pol L, Waterham HR, Ruiter JPN, Ijlst L, et al. Fatty acid oxidation flux predicts the clinical severity of VLCAD deficiency. Genet Med. 2015;17(12):989–94.CrossRefPubMed

19.

Shin-Buehring YS, Stuempfig L, Pouget E, Rahm P, Schaub J. Characterization of galactose-1-phosphate uridyl-transferase and galactokinase in human organs from the fetus and adult. Clin Chim Acta. 1981;112(3):257–65.CrossRefPubMed

Title: Profiling of intracellular metabolites produced from galactose and its potential for galactosemia research
Authors: Michel van Weeghel
Lindsey Welling
Eileen P. Treacy
Ronald J. A. Wanders
Sacha Ferdinandusse
Annet M. Bosch
Publication date: 01-12-2018
Publisher: BioMed Central
Published in: Orphanet Journal of Rare Diseases / Issue 1/2018
Electronic ISSN: 1750-1172
DOI: https://doi.org/10.1186/s13023-018-0888-1

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Profiling of intracellular metabolites produced from galactose and its potential for galactosemia research

Abstract

Background

Methods

Results

Conclusions

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2018

Pathophysiology of carotid-cavernous fistulas in vascular Ehlers-Danlos syndrome: a retrospective cohort and comprehensive review

Systemic retinoids for treatment of recalcitrant IgA pemphigus

Serial MRIs provide novel insight into natural history of optic pathway gliomas in patients with neurofibromatosis 1

Status of newborn screening and follow up investigations for Mucopolysaccharidoses I and II in Taiwan

Using a meta-narrative literature review and focus groups with key stakeholders to identify perceived challenges and solutions for generating robust evidence on the effectiveness of treatments for rare diseases

Rare disease registries: potential applications towards impact on development of new drug treatments